NCT04014556View on ClinicalTrials.gov

Aflibercept Plus Micropulse Laser Versus Aflibercept Monotherapy for Diabetic Macular Edema

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 1, 2016

Primary Completion Date

October 1, 2018

Study Completion Date

December 1, 2018

Conditions
Diabetic Macular Edema
Interventions
DEVICE

micropulse laser

"Micropulse session details:~Mainster focal grid contact lens (×1.05 laser magnification) was used to perform laser. The 577-nm yellow laser (OcuLight SLx, Iridex Corp., Mountain View, California, USA) was used. Fixed treatment parameters were used in all cases: 200-μm spot size, 200-ms exposure duration, 400-mW power, and a 5% duty cycle. Confluent applications with no spacing were administered using 5x5 grid pattern over the entire edematous area including the fovea."

DRUG

Aflibercept

Aflibercept

All Listed Sponsors
lead

University of Alexandria

OTHER

NCT04014556 - Aflibercept Plus Micropulse Laser Versus Aflibercept Monotherapy for Diabetic Macular Edema | Biotech Hunter | Biotech Hunter